Reported Earnings • Mar 25
Full year 2025 earnings released: EPS: NT$0.46 (vs NT$0.36 in FY 2024) Full year 2025 results: EPS: NT$0.46 (up from NT$0.36 in FY 2024). Revenue: NT$222.0m (up 70% from FY 2024). Net income: NT$25.0m (up 72% from FY 2024). Profit margin: 11% (in line with FY 2024). Announcement • Mar 12
Pet Pharm Biotech Co., Ltd., Annual General Meeting, Jun 25, 2026 Pet Pharm Biotech Co., Ltd., Annual General Meeting, Jun 25, 2026. Location: 6 floor no,296, chien kuo 1st rd., sinjhuang district, new taipei city Taiwan New Risk • Mar 08
New minor risk - Revenue size The company makes less than US$5m in revenue. Total revenue: NT$159m (US$5.0m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (36% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (NT$159m revenue, or US$5.0m).